Founded in April 2012 by the Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government, Bioaster Technology Research Institute (TRI) is working to develop a unique technological and innovative model to help face the latest challenges in microbiology, and in particular to:
- Fight antimicrobial resistance
- Improve the safety and efficacy of vaccines. Quickly diagnose infections at the patient’s bedside. Take full advantage of human and animal microbiota.
The aim of Bioaster is to boost the development of medical and nutritional solutions for human and animal health.
Bioaster is supported by high-profile academic and industrial partners. Since it was set up, it has coordinated over 53 research projects with 25 academic partners and 26 industry partners (source: Bioaster).
Between the phases of knowledge acquisition and providing a solution for the patient, Bioaster seeks to act as a bridge between the academic and private spheres, provide technological added value in microbiology, and is an agile and collaborative organization that reduces the risks associated with innovation.